pharmaphorum

AUGUST 23, 2022

Swiss eyecare firm Alcon has made a move to boost its position in ophthalmological medicines with a $15.25 per share offer to buy Aerie Pharmaceuticals that value the US company at around $770 million. Alcon said the Aerie deal is another example of its strategy to expand in the ophthalmic pharmaceutical eye drop space.

59

59

pharmaphorum

NOVEMBER 4, 2021

Once Roche repurchases the shares – assuming shareholders in the company agree to the deal at a meeting schedule for 26 November – they will be cancelled, and the result will be that the pool owned by shareholders of the founding Hoffmann-La Roche families in Roche will swell to around 67.5%.

105

105

PharmaShots

MAY 10, 2023

Shots: Driven by constant innovation and life-changing technological advances, medical device companies have integrated a holistic approach to diagnosis and therapeutics. in 2022, medical device companies are anticipated to touch the astronomical threshold of $965.2B. The company’s 2022 revenue surged by 4.32% vs 2021.

Nursing Homes 40

Nursing Homes Hospitals FDA Communication 40

pharmaphorum

OCTOBER 18, 2022

Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisition Corp (EBAC), a special purpose acquisition company (SPAC) that has screened over 100 European biotechnology companies.

59

59

Pharmaceutical Technology

SEPTEMBER 23, 2022

While both of these therapies compete directly against Restasis, Kala Pharmaceuticals’ Eysuvis (loteprednol etabonate suspension 0.25%), which was sold to Alcon in July 2022, is a corticosteroid used for short term treatment of the signs and symptoms of DES.

FDA 59

FDA 59

pharmaphorum

OCTOBER 29, 2020

Earlier this year, the group also signed a licensing deal with Dyno Therapeutics for its AAV capsid-based gene delivery technology, also focused on ocular disease which remains one of Novartis’ core drug development targets despite the spin-off of the Alcon eyecare division in 2019.

40

40

PharmaShots

APRIL 13, 2023

While the recent COVID-19 pandemic served as an instigator for the biopharma industry by encouraging companies to assess the key performance indicators and meet the unmet demands, some other notable factors, such as mapping of the human genome, and the development of automated DNA sequencers acted as driving forces for the industry.

Vaccines 40

Vaccines Pharmaceutical Companies Pharmaceutical Companies Labelling 40